Studies of a prophylactic HIV-1 vaccine candidate based on modified vaccinia virus Ankara (MVA) with and without DNA priming: effects of dosage and route on safety and immunogenicity. Vaccine, 25(11), 2120-7. presented at the 2007 Mar 01. doi:10.1016/j.vaccine.2006.11.016. (2007).
A phase 1 study to evaluate the safety and immunogenicity of a recombinant HIV type 1 subtype C adeno-associated virus vaccine. AIDS Res Hum Retroviruses, 24(6), 873-80. presented at the 2008 Jun. doi:10.1089/aid.2007.0292. (2008).
Safety and immunogenicity of recombinant low-dosage HIV-1 A vaccine candidates vectored by plasmid pTHr DNA or modified vaccinia virus Ankara (MVA) in humans in East Africa. Vaccine, 26(22), 2788-95. presented at the 2008 May 23. doi:10.1016/j.vaccine.2008.02.071. (2008).
MELD score is an important predictor of pretransplantation mortality in HIV-infected liver transplant candidates. Gastroenterology, 138(1), 159-64. presented at the 2010 Jan. doi:10.1053/j.gastro.2009.09.053. (2010).
Outcomes of kidney transplantation in HIV-infected recipients. N Engl J Med, 363(21), 2004-14. presented at the 2010 Nov 18. doi:10.1056/NEJMoa1001197. (2010).
A phase 2 study to evaluate the safety and immunogenicity of a recombinant HIV type 1 vaccine based on adeno-associated virus. AIDS Res Hum Retroviruses, 26(8), 933-42. presented at the 2010 Aug. doi:10.1089/aid.2009.0242. (2010).
Background morbidity in HIV vaccine trial participants from various geographic regions as assessed by unsolicited adverse events. Hum Vaccin Immunother, 8(5), 630-8. presented at the 2012 May. doi:10.4161/hv.19454. (2012).
Malignancy in the HIV-infected patients undergoing liver and kidney transplantation. Curr Opin Oncol, 24(5), 517-21. presented at the 2012 Sep. doi:10.1097/CCO.0b013e328355e0d7. (2012).
Outcomes of liver transplant recipients with hepatitis C and human immunodeficiency virus coinfection. Liver Transpl, 18(6), 716-26. presented at the 2012 Jun. doi:10.1002/lt.23411. (2012).
A phase I double blind, placebo-controlled, randomized study of a multigenic HIV-1 adenovirus subtype 35 vector vaccine in healthy uninfected adults. PLoS One, 7(8), e41936. presented at the 2012. doi:10.1371/journal.pone.0041936. (2012).
Safety and adherence to intermittent pre-exposure prophylaxis (PrEP) for HIV-1 in African men who have sex with men and female sex workers. PLoS One, 7(4), e33103. presented at the 2012. doi:10.1371/journal.pone.0033103. (2012).
Surgical complications in 275 HIV-infected liver and/or kidney transplantation recipients. Surgery, 152(3), 376-81. presented at the 2012 Sep. doi:10.1016/j.surg.2012.06.012. (2012).
Changes in clearance, volume and bioavailability of immunosuppressants when given with HAART in HIV-1 infected liver and kidney transplant recipients. Biopharm Drug Dispos, 34(8), 442-51. presented at the 2013 Nov. doi:10.1002/bdd.1860. (2013).
Chronic kidney disease after liver transplantation in human immunodeficiency virus/hepatitis C virus-coinfected recipients versus human immunodeficiency virus-infected recipients without hepatitis C virus: results from the National Institutes of Health mu. Liver Transpl, 19(6), 619-26. presented at the 2013 Jun. doi:10.1002/lt.23648. (2013).
Phenotypic analysis of NS5A variant from liver transplant patient with increased cyclosporine susceptibility. Virology, 436(2), 268-73. presented at the 2013 Feb 20. doi:10.1016/j.virol.2012.11.018. (2013).
Safety, adherence and acceptability of intermittent tenofovir/emtricitabine as HIV pre-exposure prophylaxis (PrEP) among HIV-uninfected Ugandan volunteers living in HIV-serodiscordant relationships: a randomized, clinical trial. PLoS One, 8(9), e74314. presented at the 2013. doi:10.1371/journal.pone.0074314. (2013).
Acceptability and feasibility of repeated mucosal specimen collection in clinical trial participants in Kenya. PLoS One, 9(10), e110228. presented at the 2014. doi:10.1371/journal.pone.0110228. (2014).
Best single time point correlations with AUC for cyclosporine and tacrolimus in HIV-infected kidney and liver transplant recipients. Transplantation, 97(6), 702-7. presented at the 2014 Mar 27. doi:10.1097/01.TP.0000441097.30094.31. (2014).
Vitamin D status of human immunodeficiency virus-positive patients with advanced liver disease enrolled in the solid organ transplantation in HIV: multi-site study. Liver Transpl, 20(2), 156-64. presented at the 2014 Feb. doi:10.1002/lt.23784. (2014).
Immunologic Predictors of Liver Transplantation Outcomes in HIV-HCV Co-Infected Persons. PLoS One, 10(8), e0135882. presented at the 2015. doi:10.1371/journal.pone.0135882. (2015).
A Phase I Double Blind, Placebo-Controlled, Randomized Study of the Safety and Immunogenicity of an Adjuvanted HIV-1 Gag-Pol-Nef Fusion Protein and Adenovirus 35 Gag-RT-Int-Nef Vaccine in Healthy HIV-Uninfected African Adults. PLoS One, 10(5), e0125954. presented at the 2015. doi:10.1371/journal.pone.0125954. (2015).
Understanding Adherence to Daily and Intermittent Regimens of Oral HIV Pre-exposure Prophylaxis Among Men Who Have Sex with Men in Kenya. AIDS Behav, 19(5), 794-801. presented at the 2015 May. doi:10.1007/s10461-014-0958-x. (2015).
Broad HIV-1 inhibition in vitro by vaccine-elicited CD8(+) T cells in African adults. Mol Ther Methods Clin Dev, 3, 16061. presented at the 2016. doi:10.1038/mtm.2016.61. (2016).
Efficacy of a Russian-backbone live attenuated influenza vaccine among young children in Bangladesh: a randomised, double-blind, placebo-controlled trial. Lancet Glob Health, 4(12), e946-e954. presented at the 2016 12. doi:10.1016/S2214-109X(16)30200-5. (2016).
Survival in HIV-positive transplant recipients compared with transplant candidates and with HIV-negative controls. AIDS, 30(3), 435-44. presented at the 2016 Jan 28. doi:10.1097/QAD.0000000000000934. (2016).